Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pipeline Watch: Phase III Starts With Bavencio, MultiStem And VT-1161

Executive Summary

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

You may also be interested in...



Early-Stage Cell And Gene Therapy Progress: Updates From Casebia, BlueRock, Athersys, Cynata

Scrip caught up with several companies during the recent Cell and Gene Meeting on the Mesa, sponsored by the Alliance for Regenerative Medicine.

Pipeline Watch: Phase III Starts In RSV Prophlyaxis, Dry Eye Disease

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Jefferies' Survey Predicts M&A Rebound In 2021

An upturn in M&A activity across the whole healthcare sector is expected in 2021, with the COVID-19 pandemic and the associated development of a vaccine shining a light on the sector, says a recent survey by Jefferies. 

Topics

Related Companies

UsernamePublicRestriction

Register

SC143384

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel